FDA approves Merck's oral PCSK9 inhibitor Lipfendra for high cholesterol
Lipfendra cut LDL-C 56% versus placebo at 24 weeks in the CORALreef Lipids trial, becoming the first FDA-approved oral PCSK9 inhibitor in a field long dominated by injectables.
Executive Summary
- The FDA approved Merck's oral PCSK9 inhibitor for adults with high cholesterol, including a familial form of the disease, based on a completed Phase 3 trial.
- The pivotal trial showed a placebo-adjusted LDL-C reduction that cleared statistical significance, with a safety profile that tracked closely with placebo.
- Every other PCSK9 inhibitor on the market or in late-stage testing for this indication is delivered by injection or infusion; this is the first approved as a once-daily pill.
- The approval does not introduce a new mechanism to a crowded field, but it does introduce a new route to a class that has been route-constrained since its first approvals.
The approval
Merck announced on July 16, 2026, that the FDA approved Lipfendra (enlicitide) 20 mg tablets as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The approval rests on the Phase 3 CORALreef Lipids trial (NCT05952856), a randomized, placebo-controlled, triple-masked study that enrolled 2,912 patients and completed in July 2025. "By harnessing the innovative science of PCSK9 inhibitors and novel macrocyclic peptide technology, LIPFENDRA was designed to significantly lower LDL-C in the form of a convenient once-daily pill," said Dean Y. Li, president of Merck Research Laboratories. Merck’s+1Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with HypercholesterolemiaJul 16, 2026A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsNCT05952856
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The result
At week 24, Lipfendra reduced LDL-C by 57% from baseline, a 56% placebo-adjusted reduction (95% CI: -61, -51; p<0.001), against a 3% increase from baseline in the placebo arm. A post-hoc analysis that removed biologically implausible baseline LDL-C values under revised data-handling rules showed a 60% reduction from baseline. The trial also showed reductions in non-HDL cholesterol and apolipoprotein B, two other markers tied to atherosclerotic cardiovascular disease risk. The safety profile in CORALreef Lipids was similar to placebo, and discontinuation rates due to adverse reactions were comparable between arms. Merck’sMerck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with HypercholesterolemiaJul 16, 2026
How the trial ran
CORALreef Lipids randomized patients 2,912 patients across two arms, drug versus placebo, in a Phase 3, triple-masked design that enrolled at sites in the United States, Japan, China, South Korea, and Israel. Its registered primary endpoints covered the mean percent change in LDL-C at week 24 alongside the incidence of treatment-emergent adverse events and drug discontinuations due to adverse events, meaning the trial was built to establish both an efficacy signal and a tolerability profile in the same population. The trial's primary completion date shifted once, from September 2025 to August 2025, and its enrollment count grew modestly from 2,760 to 2,912 by the time it completed, both changes within the routine range for a trial of this size. NCT05952856A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsNCT05952856
The competitive field
PCSK9 inhibition is a validated mechanism with four monoclonal antibodies, siRNA agents, and other biologics already approved for hypercholesterolemia, including Novartis's inclisiran (Leqvio) and Amgen's evolocumab (Repatha). All of those approved options are injected, dosed by subcutaneous injection every few weeks to twice yearly. Lipfendra is a small-molecule macrocyclic peptide taken as a daily oral tablet, the only route among the direct comparators tracked for this target-indication pair that is oral rather than injected. The intended advantage is convenience and avoidance of injection-site burden; the trade-off, untested by this approval, is whether daily oral dosing sustains adherence and LDL-C control as well as infrequent injectables do over years of use. Novartis is running its own inclisiran trial in a related cardiovascular population (NCT06941792), underscoring that the injectable incumbents are still expanding their own evidence base rather than ceding ground.
What comes next
Merck is running an ongoing cardiovascular outcomes trial, CORALreef Outcomes, to test whether Lipfendra reduces cardiovascular morbidity and mortality, a question this approval does not answer. The FDA granted enlicitide a Commissioner's National Priority Voucher in December 2025 for the CORALreef program, a designation tied to the broader development effort rather than to this specific LDL-C approval. The company said it plans to share the CORALreef Lipids and CORALreef HeFH data with regulators worldwide, extending the filing beyond the U.S.. Merck’sMerck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with HypercholesterolemiaJul 16, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.